PathMaker Neurosystems completes ALS Early Feasibility Study — presents results at MDA Conference March 2026
Summary
PathMaker Neurosystems announced completion of their ALS Early Feasibility Study and presentation of results at the 2026 MDA (Muscular Dystrophy Association) Clinical & Scientific Conference in March 2026. PathMaker's non-invasive wearable neurostimulation system uses transcutaneous spinal cord stimulation to modulate motor circuits in ALS patients — providing a non-surgical neuromodulation option for a patient population where invasive implants are often contraindicated due to disease progression. EFS completion enables the company to advance toward a larger, potentially pivotal study for this devastating and rapidly progressive disease.
Why it matters
ALS EFS completion from a non-invasive spinal cord stimulator is clinically meaningful because ALS patients are often excluded from invasive device studies due to progression risk and survival considerations. A non-invasive device that meaningfully modulates motor function in ALS would be highly adoptable — no surgical risk, no explant needed as disease progresses, and potentially combinable with standard of care riluzole without interaction concerns.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial